{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:03:23Z","timestamp":1794373403443,"version":"4.9.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Hemolytic disease of the fetus and newborn (HDFN) is a severe disease, resulting from maternal red cell (RBC) alloantibodies directed against fetal RBCs. The effect of a first\u2010trimester antibody screening program on the timely detection of HDFN caused by antibodies other than anti\u2010D was evaluated.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Nationwide, all women (1,002 in 305,000 consecutive pregnancies during 18\u2003months) with alloantibodies other than anti\u2010D, detected by a first\u2010trimester antibody screen, were included in a prospective index\u2010cohort study. In a parallel\u2010coverage validation study, patients with HDFN caused by antibodies other than anti\u2010D, that were missed by the screening program, were retrospectively identified.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> The prevalence of positive antibody screens at first\u2010trimester screening was 1,232 in 100,000; the prevalence of alloantibodies other than anti\u2010D was 328 in 100,000, of which 191 of 100,000 implied a risk for occurrence of HDFN because the father carried the antigen. Overall, severe HDFN, requiring intrauterine or postnatal (exchange) transfusions, occurred in 3.7\u2003percent of fetuses at risk: for anti\u2010K in 11.6\u2003percent; anti\u2010c in 8.5\u2003percent; anti\u2010E in 1.1\u2003percent; Rh antibodies other than anti\u2010c, anti\u2010D, or anti\u2010E in 3.8\u2003percent; and for antibodies other than Rh antibodies or anti\u2010K, in none of the fetuses at risk. All affected children, where antibodies were detected, were promptly treated and healthy at the age of 1\u2003year. The coverage validation study showed a sensitivity of the screening program of 75\u2003percent. Five of 8 missed cases were caused by anti\u2010c, with delay\u2010induced permanent damage in at least 1.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> First\u2010trimester screening enables timely treatment of HDFN caused by antibodies other than anti\u2010D, however, with a sensitivity of only 75\u2003percent. A second screening at Week\u200330 of c\u2013 women will enhance the screening program. Severe HDFN, caused by antibodies other than anti\u2010D, is associated with anti\u2010K, anti\u2010c, and to a lesser extent with other Rh\u2010alloantibodies.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2007.01625.x","type":"journal-article","created":{"date-parts":[[2008,2,2]],"date-time":"2008-02-02T04:40:17Z","timestamp":1201927217000},"page":"941-952","source":"Crossref","is-referenced-by-count":195,"title":["Effect of screening for red cell antibodies, other than anti\u2010D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands"],"prefix":"10.1111","volume":"48","author":[{"given":"J.M.","family":"Koelewijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.G.M.","family":"Vrijkotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Van Der Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Bonsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812103392410"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1939.72800270002007a"},{"key":"e_1_2_7_4_2","first-page":"390","volume-title":"Blood transfusion in clinical medicine","author":"Mollison PL","year":"1997"},{"key":"e_1_2_7_5_2","first-page":"1","volume-title":"Alloimmune disorders of pregnancy","author":"Daniels G","year":"2002"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1054\/blre.1999.0123"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(00)00428-0"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.007"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(86)90398-4"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70425-8"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1986.tb07829.x"},{"key":"e_1_2_7_12_2","volume-title":"Blood testing in pregnancy. Pregnancy immunization, hepatitis B and lues [booklet in Dutch]","author":"Council of Health Insurances.","year":"1998"},{"key":"e_1_2_7_13_2","volume-title":"Principles and practice of screening for disease","author":"Wilson JM","year":"1968"},{"key":"e_1_2_7_14_2","volume-title":"Perinatal care in the Netherlands 2003 [in Dutch].","author":"Stichting Perinatale Registratie Nederland.","year":"2006"},{"key":"e_1_2_7_15_2","volume-title":"Process monitoring pre\u2010 and postnatal screenings 2003 [report in Dutch].","author":"Van Der Ploeg CP","year":"2006"},{"key":"e_1_2_7_16_2","volume-title":"Guide line blood transfusion","author":"Quality Institute of Healthcare and evidence\u2010based guideline development (CBO).","year":"2004"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052855"},{"key":"e_1_2_7_18_2","volume-title":"Red cell immunization and pregnancy","author":"Vandenbussche FP","year":"2002"},{"key":"e_1_2_7_19_2","volume-title":"The blood group antigen facts book.","author":"Reid M","year":"2004"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1981.tb00948.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21307\/immunohematology-2019-484","article-title":"Antibodies detected in samples from 21,730 pregnant women","volume":"19","author":"Jovanovic\u2010Srzentic S","year":"2003","journal-title":"Immunohematol"},{"key":"e_1_2_7_22_2","first-page":"2523","article-title":"[The incidence of irregular antibodies in pregnancy: a prospective study in the region of the s\u2010Hertogenbosch]","volume":"143","author":"De Vrijer B","year":"1999","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000109206.22354.2C"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000149153.93417.66"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1986.tb07828.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349509021175"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349309021130"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2002.810506.x"},{"key":"e_1_2_7_29_2","first-page":"1145","article-title":"Is a third\u2010trimester antibody screen in Rh+ women necessary?","volume":"5","author":"Rothenberg JM","year":"1999","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33393174447.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00764.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.10.895"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.06.063"},{"key":"e_1_2_7_34_2","first-page":"135","volume-title":"The blood group antigen facts book.","author":"Reid M","year":"2004"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2007.01625.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2007.01625.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:05:01Z","timestamp":1697281501000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2007.01625.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1537-2995.2007.01625.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01625.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}